Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antigenicity of influenza virus hemagglutinin following chemical modification

Identifieur interne : 002742 ( Main/Exploration ); précédent : 002741; suivant : 002743

Antigenicity of influenza virus hemagglutinin following chemical modification

Auteurs : W. Graeme Laver [Australie] ; Gillian M. Air [Australie] ; Robert G. Webster [États-Unis]

Source :

RBID : ISTEX:A47A1662186ED86E4C8C3A2286FE5086F35F8B44

English descriptors

Abstract

Abstract: Hemagglutinin (HA) molecules from a number of different strains of type A influenza virus were reacted with 1-fluoro 2–4-dinitrobenzene (FDNB) at pH values ranging from 8.4 to 10.3. HA was also reacted with tetranitromethane (TNM) or diazotized sulfanilic acid (DSA). Sequence studies on HA1 from HA molecules treated with FDNB, TNM, or DSA showed that certain lysine, tyrosine, or histidine residues were 100% substituted after the reaction, while others apparently did not react at all. DNP-substituted hemagglutinin molecules, isolated from FDNB-treated A/Memphis/1/71H-BELN(H3N1) virus particles, had up to 58% of lysines substituted with DNP. These molecules, nevertheless, retained hemagglutinin activity and, as far as could be measured, the same capacity as the unsubstituted hemagglutinin to react with heterogeneous antiserum or a panel of monoclonal antibodies. These results suggest that those amino acid side chains able to react with FDNB (lysine, histidine, tyrosine, and cysteine) are either not present in the antigenic sites on the HA, or if they are, then either the side chains which bind antibody do not react with DNP, or the presence of DNP in the site does not affect its ability to combine with antibody. The results also suggest that substitution of more than half of the lysine in the hemagglutinin molecule does not cause any marked conformational changes, for such changes would be expected to affect the ability of the HA to combine with both cell receptors and antibody molecules. Similar findings with TNM-treated HA suggest that tyrosine is not an essential part of any antigenic site on H3 type HA. HA treated with diazotized sulfanilic acid lost HA activity, but its antigenicity was similar to that of untreated HA when tested with heterogeneous antisera, suggesting that histidine was not present in the antigenic sites. However, when HA from a monoclonal variant of A/Mem/1/71 (H3N2) virus with a sequence change from wild-type in HA1 of proline (143) to histidine (Laver, Air, and Webster, 1981) was reacted with diazotized sulfanilic acid, the histidine at position 143 in HA1 reacted completely and the HA lost the ability to bind antibody specific for the new antigenic site on this variant. However, treatment of this variant with FDNB did not lead to substitution of histidine 143.

Url:
DOI: 10.1016/0042-6822(81)90355-X


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Antigenicity of influenza virus hemagglutinin following chemical modification</title>
<author>
<name sortKey="Graeme Laver, W" sort="Graeme Laver, W" uniqKey="Graeme Laver W" first="W." last="Graeme Laver">W. Graeme Laver</name>
</author>
<author>
<name sortKey="Air, Gillian M" sort="Air, Gillian M" uniqKey="Air G" first="Gillian M." last="Air">Gillian M. Air</name>
</author>
<author>
<name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G." last="Webster">Robert G. Webster</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A47A1662186ED86E4C8C3A2286FE5086F35F8B44</idno>
<date when="1981" year="1981">1981</date>
<idno type="doi">10.1016/0042-6822(81)90355-X</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-PDMWRN1J-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F46</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F46</idno>
<idno type="wicri:Area/Istex/Curation">000F46</idno>
<idno type="wicri:Area/Istex/Checkpoint">001374</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001374</idno>
<idno type="wicri:doubleKey">0042-6822:1981:Graeme Laver W:antigenicity:of:influenza</idno>
<idno type="wicri:Area/Main/Merge">002887</idno>
<idno type="wicri:Area/Main/Curation">002742</idno>
<idno type="wicri:Area/Main/Exploration">002742</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Antigenicity of influenza virus hemagglutinin following chemical modification</title>
<author>
<name sortKey="Graeme Laver, W" sort="Graeme Laver, W" uniqKey="Graeme Laver W" first="W." last="Graeme Laver">W. Graeme Laver</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The John Curtin School of Medical Research, Australian National University, Canberra, A.C.T.</wicri:regionArea>
<wicri:noRegion>A.C.T.</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Air, Gillian M" sort="Air, Gillian M" uniqKey="Air G" first="Gillian M." last="Air">Gillian M. Air</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The John Curtin School of Medical Research, Australian National University, Canberra, A.C.T.</wicri:regionArea>
<wicri:noRegion>A.C.T.</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G." last="Webster">Robert G. Webster</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>St Jude Children's Research Hospital, 332 N. Lauderdale, P.O. Box 318, Memphis, Tennessee, 38101</wicri:regionArea>
<wicri:noRegion>38101</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Virology</title>
<title level="j" type="abbrev">YVIRO</title>
<idno type="ISSN">0042-6822</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1981">1981</date>
<biblScope unit="volume">111</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="538">538</biblScope>
<biblScope unit="page" to="548">548</biblScope>
</imprint>
<idno type="ISSN">0042-6822</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0042-6822</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Academic press</term>
<term>Amino</term>
<term>Amino acid sequence</term>
<term>Amino acids</term>
<term>Antibody molecules</term>
<term>Antigenic</term>
<term>Antigenic site</term>
<term>Antigenic sites</term>
<term>Bind antibody</term>
<term>Cell biology</term>
<term>Cellulose acetate strips</term>
<term>Chemical modification</term>
<term>Conformational changes</term>
<term>Diazotized</term>
<term>Diazotized sulfanilic acid</term>
<term>Elsevier</term>
<term>Fdnb</term>
<term>Haemagglutinin</term>
<term>Hemagglutinin</term>
<term>Hemagglutinin activity</term>
<term>Hemagglutinin molecule</term>
<term>Hemagglutinin molecules</term>
<term>Histidine</term>
<term>Histidine residues</term>
<term>Hong kong</term>
<term>Hyperimmune</term>
<term>Immunodiffusion tests</term>
<term>Influenza</term>
<term>Influenza virus</term>
<term>Influenza virus hemagglutinin</term>
<term>Laver</term>
<term>Lysine</term>
<term>Lysine residues</term>
<term>Molecule</term>
<term>Monoclonal</term>
<term>Monoclonal antibodies</term>
<term>Monoclonal antibody</term>
<term>Monoclonal hybridoma antibodies</term>
<term>Monoclonal variant</term>
<term>Monoclonal variants</term>
<term>Nonoverlapping antigenic areas</term>
<term>Peptide</term>
<term>Polypeptide</term>
<term>Reagent</term>
<term>Sequence change</term>
<term>Soluble tryptic peptides</term>
<term>Specific antibody</term>
<term>Sulfanilic</term>
<term>Tetranitromethane</term>
<term>Tyrosine</term>
<term>Tyrosine residues</term>
<term>Untreated</term>
<term>Untreated virus</term>
<term>Variant</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus particles</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Hemagglutinin (HA) molecules from a number of different strains of type A influenza virus were reacted with 1-fluoro 2–4-dinitrobenzene (FDNB) at pH values ranging from 8.4 to 10.3. HA was also reacted with tetranitromethane (TNM) or diazotized sulfanilic acid (DSA). Sequence studies on HA1 from HA molecules treated with FDNB, TNM, or DSA showed that certain lysine, tyrosine, or histidine residues were 100% substituted after the reaction, while others apparently did not react at all. DNP-substituted hemagglutinin molecules, isolated from FDNB-treated A/Memphis/1/71H-BELN(H3N1) virus particles, had up to 58% of lysines substituted with DNP. These molecules, nevertheless, retained hemagglutinin activity and, as far as could be measured, the same capacity as the unsubstituted hemagglutinin to react with heterogeneous antiserum or a panel of monoclonal antibodies. These results suggest that those amino acid side chains able to react with FDNB (lysine, histidine, tyrosine, and cysteine) are either not present in the antigenic sites on the HA, or if they are, then either the side chains which bind antibody do not react with DNP, or the presence of DNP in the site does not affect its ability to combine with antibody. The results also suggest that substitution of more than half of the lysine in the hemagglutinin molecule does not cause any marked conformational changes, for such changes would be expected to affect the ability of the HA to combine with both cell receptors and antibody molecules. Similar findings with TNM-treated HA suggest that tyrosine is not an essential part of any antigenic site on H3 type HA. HA treated with diazotized sulfanilic acid lost HA activity, but its antigenicity was similar to that of untreated HA when tested with heterogeneous antisera, suggesting that histidine was not present in the antigenic sites. However, when HA from a monoclonal variant of A/Mem/1/71 (H3N2) virus with a sequence change from wild-type in HA1 of proline (143) to histidine (Laver, Air, and Webster, 1981) was reacted with diazotized sulfanilic acid, the histidine at position 143 in HA1 reacted completely and the HA lost the ability to bind antibody specific for the new antigenic site on this variant. However, treatment of this variant with FDNB did not lead to substitution of histidine 143.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>États-Unis</li>
</country>
</list>
<tree>
<country name="Australie">
<noRegion>
<name sortKey="Graeme Laver, W" sort="Graeme Laver, W" uniqKey="Graeme Laver W" first="W." last="Graeme Laver">W. Graeme Laver</name>
</noRegion>
<name sortKey="Air, Gillian M" sort="Air, Gillian M" uniqKey="Air G" first="Gillian M." last="Air">Gillian M. Air</name>
</country>
<country name="États-Unis">
<noRegion>
<name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G." last="Webster">Robert G. Webster</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002742 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002742 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A47A1662186ED86E4C8C3A2286FE5086F35F8B44
   |texte=   Antigenicity of influenza virus hemagglutinin following chemical modification
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021